ACRS: Rega marang dodolan Aclaris Therapeutics Inc.

Logo korporat perusahaan Aclaris Therapeutics Inc. (ACRS)

Clinical failure risks and patent disputes are weighing on Aclaris Therapeutics (ACRS). However, the intellectual property licensing strategy minimizes costs, creating a foundation for free cash flow growth. The P/S multiple trend confirms this balance, with the metric reaching 91.90. The small molecule pipeline, targeting hypertrophic immune pathologies, further validates this efficiency.

Multiplikator P/S: Aclaris Therapeutics, Inc. (ACRS) kanggo 04.07.2022 - 16.11.2026

Rincian analitis perusahaan Aclaris Therapeutics, Inc (ACRS)

Analisis fundamental perusahaan:Aclaris Therapeutics, Inc., ACRS
Sampel barang Aclaris

Aclaris Therapeutics' development of immunological drugs with long-term therapeutic effects establishes a foundation for stable future cash flows. The relationship between market value and sales volume, reflected through the price-to-sales ratio, allows for an assessment of how cost-push inflation impacts margins and helps distinguish fundamental growth from speculation, preventing the acquisition of the asset at its valuation peak.

Perusahaan pesaing

argenx - Rasio kapitalisasi marang pendapatan|Multiplikator P/S BNTX (biontech.de)|Abivax Corp (ABVX) - Rega marang dodolan|ADMA Corp - Multiplikator P/S|Rasio rega marang dodolan PTGX|Immunovant Inc (IMVT) - Rasio rega marang pendapatan|KNSA - Koefisien rega marang pendapatan|GRFS (Grifols Biemat) - Multiplikator P/S|Multiplikator P/S Adaptive Biotechnologies Inc.|Rasio rega marang pendapatan Celldex Therapeutics (CLDX)|Koefisien rega marang pendapatan auriniapharma.com|Rasio rega marang pendapatan BioCryst Pharmaceuticals BCRX|Rasio kapitalisasi pasar marang pendapatan VERA|Dianthus Pharma - Multiplikator P/S|PHVS - Multiplikator P/S|ABCL: Multiplikator P/S|TRML (Tourmaline Bio, Inc.) - Rasio rega marang pendapatan|Rasio rega marang pendapatan Intrexon|PHAR - Multiplikator rega marang pendapatan|Multiplikator P/S NKTR|Rasio rega marang pendapatan UPB (Upstream Bio Corp)|Rasio rega marang pendapatan Zenas Biopharma, Inc. ZBIO|Koefisien rega marang pendapatan immunome.com (IMNM)|Gossamer Bio Inc - Multiplikator P/S|Rasio kapitalisasi pasar marang pendapatan KALV (KalVista Pharmaceuticals, Inc.)|SEPN: Multiplikator P/S|Kapitalisasi marang pendapatan Pieris Pharmaceuticals Inc|Kapitalisasi marang pendapatan SVRA|Kapitalisasi marang pendapatan Rigel Pharmaceuticals (RIGL)|Multiplikator P/S ANAB|ATXS - Rega marang dodolan|Rasio rega marang pendapatan enGene Corp ENGN|Koefisien rega marang pendapatan RAPT Therapeutics, Inc. (RAPT)|Aerovate - Multiplikator P/S|KYTX - Multiplikator P/S|TLSA: Multiplikator P/S|Kapitalisasi marang pendapatan Cabaletta Bio, Inc|Rasio rega marang pendapatan Ventyx Biosciences, Inc|THTX: Rasio kapitalisasi pasar marang pendapatan|Kapitalisasi marang pendapatan AVTX (Avalo Therapeutics, Inc)|Kapitalisasi marang pendapatan Eledon Pharmaceuticals ELDN|Rasio rega marang pendapatan Agenus, Inc. AGEN|Multiplikator P/S Climb Bio Inc. CLYM|ZURA - Rasio rega marang pendapatan|Rasio rega marang dodolan ATYR|ADAG (Adagene Inc.) - Kapitalisasi marang pendapatan|ImageneBio Inc (IMA) - Multiplikator P/S|Rasio rega marang pendapatan Shattuck Therapeutics|Kapitalisasi marang pendapatan equilliumbio.com (EQ)|Multiplikator P/S CNTB|Koefisien rega marang pendapatan Immunic Therapeutics|Multiplikator P/S ATRA (Atara Biotherapeutics, Inc.)|IFRX - Kapitalisasi marang pendapatan|Rasio kapitalisasi pasar marang pendapatan X4 Pharmaceuticals, Inc. (XFOR)|ACET (adicetbio.com) - Rasio kapitalisasi marang pendapatan|CELU: Multiplikator P/S|INMB - Koefisien rega marang pendapatan|Rasio rega marang pendapatan Barinthus Biotherapeutics plc|KZR: Rasio kapitalisasi pasar marang pendapatan|Multiplikator P/S SABS|AKTX (Akari Therapeutics Plc) - Rasio kapitalisasi pasar marang pendapatan|Multiplikator P/S ENLV (Enlivex Therapeutics Ltd)|q32bio.com - Rasio rega marang pendapatan|GOVX: Kapitalisasi marang pendapatan|edesabiotech.com (EDSA) - Kapitalisasi marang pendapatan|IBIO: Multiplikator P/S|CARM - Koefisien rega marang pendapatan|Kapitalisasi marang pendapatan XTLB|Kapitalisasi marang pendapatan boltbio.com (BOLT)|Rasio rega marang pendapatan HCW Biologics Inc (HCWB)|Multiplikator P/S Aptevo Therapeutics, Inc. (APVO)|Rasio rega marang pendapatan aimimmuno.com AIM|Rasio kapitalisasi pasar marang pendapatan ADTX|GRI Bio Corporation - Multiplikator P/S|XORTX Corp (XRTX) - Kapitalisasi marang pendapatan|HIND (Vyome Holdings Inc.) - Kapitalisasi marang pendapatan|revbiosciences.com (REVB) - Multiplikator P/S|INDP (Indaptus Corp) - Multiplikator P/S|Kapitalisasi marang pendapatan Scinai Immunotherapeutics Ltd (SCNI)|Rasio rega marang pendapatan CalciMedica Inc (CALI)|AFMD (Affimed NV) - Rasio kapitalisasi pasar marang pendapatan|Multiplikator P/S ALLK (Allakos Inc.)|Multiplikator P/S HOOKIPA HOOK|IGMS: Kapitalisasi marang pendapatan|Rasio kapitalisasi pasar marang pendapatan ITOS (iTeos)|OCEA: Multiplikator P/S|TCBP (TC BioPharm Ltd) - Rasio rega marang pendapatan|THRD (Third Harmonic Bio Inc) - Multiplikator P/S